What's behind Alnylam Pharmaceuticals' latest 3.4% stock surge?

Traders Union
All News
Stocks
Alnylam rises 3.4% today to $226.44

Highlights

Alnylam Pharmaceuticals’ TTR amyloidosis franchise exceeded $1 billion in quarterly revenue, led by robust AMVUTTRA growth.
The company initiated Phase II trials in von Willebrand disease and Down syndrome–associated Alzheimer's, reinforcing its pipeline expansion strategy.
Shares of Alnylam remain under persistent selling pressure below key averages, with a short-term trading range expected between $210.34 and $242.53.

Revenue milestone and growth plans as second-line demand normalizes

Alnylam Pharmaceuticals reported its TTR amyloidosis franchise surpassed $1 billion in revenues for the first time during the second quarter of 2026, fueled by growth in AMVUTTRA. The company adjusted its full-year product revenue guidance to reflect a normalization in second-line demand. Alnylam has also started Phase II trials for ALN-6400 in von Willebrand disease and mivelsiran in Down syndrome associated Alzheimer's, with multiple new IND filings planned as part of its long-term growth strategy.

Anton Kharitonov, expert at Traders Union, notes that ALNY’s technical setup remains broadly bearish. The stock’s inability to reclaim any key moving average signals sellers maintain control across all timeframes. He points out that oversold technicals have not triggered sustained inflow, while revenue guidance normalization indicates management’s caution. Momentum readings affirm there is little support for a substantial rebound. "Despite a revenue milestone, short-term bounces look fragile — I expect downside risk to dominate until clear accumulation emerges."

Viktoras Karapetjanc, expert at Traders Union, sees promise in Alnylam’s landmark $1 billion TTR franchise and long-term R&D pipeline. He emphasizes that fresh IND filings and Phase II program launches sustain the company’s structural growth story. The new product cycle and leadership in amyloidosis support forward-looking investor confidence. Strong franchise performance creates a foundation for expansion despite technical volatility. "This market offers multiple setups — as long as the bullish structure persists and pipeline progress continues, further growth is on the horizon for ALNY."

Jainam Mehta, market strategist, highlights the conflicting signals from deep oversold readings versus weak trend momentum. He suggests the current intraday volatility could set up for tactical reversals if $221.5 holds as support. With newsflow and technicals diverged, Mehta sees potential for opportunistic trades contingent on price reaction to this week’s range highs and lows. "A bounce above $229.65 may unlock a short-term breakout, but I would fade rallies that fail to clear resistance on volume."

Bearish momentum deepens as ALNY trades below all moving averages

ALNY is trading at $226.44, below its 20-day, 50-day, and 200-day moving averages ($269.47, $284.93, and $346.79, respectively). This confirms prevailing seller pressure for short-, medium-, and long-term trends, with the nearest ceiling at $229.65 and the floor at $221.5. Momentum readings remain negative: the MACD and ADX signal weak and bearish momentum. The RSI at 30.97 and CCI at -144.4 indicate oversold conditions, while Stochastic RSI is neutral. Bull/Bear Power (BBP) is at -27.76, confirming sellers are in control intraday with an oversold forecast. The Awesome Oscillator (AO) also signals bearish momentum. The stock is up $7.44 or 3.4% with an upside gap of $2.74 (1.25%), trading mid-range for the session and intraday volatility stands at 3.68%. The stock is attempting a rebound from oversold levels, but momentum signals broadly confirm persistent downside pressure.

Earlier, analysts noted that Alnylam Pharmaceuticals continued to face sustained bearish technical pressure despite moments of short-term rebound. The latest data confirm this prevailing weakness, with technical momentum still negative and downside risk heightened, making $229.65 a critical level to watch for any potential shift out of the current trading range.

Source of Data: ALNY Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.